TradeUP Acquisition Corp.

TradeUP Acquisition Corp.

UPTDU
TradeUP Acquisition Corp.US flagNASDAQ Capital Market
9.78
USD
-0.24
- -
21.20MMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Jianwei Li
Sector
Financial Services
Industry
Shell Companies
Address
437 Madison Avenue New York City NY United States of America 10022
IPO Date
Jul 15, 2021
Business
TradeUP Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in 2021 and headquartered in New York, New York. Originally formed to effect mergers, acquisitions, and business combinations, it completed a significant business combination in 2023 with Estrella Biopharma, Inc., a preclinical-stage biopharmaceutical company specializing in the development of T-cell therapies targeting blood cancers and solid tumors. The combined entity, now trading under the name Estrella Immunopharma, Inc., focuses on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies, including lead candidates EB103 and EB104, designed to improve outcomes for patients with B-cell leukemias, lymphomas, and solid tumors. Estrella Immunopharma also collaborates with Imugene Limited to research a combined treatment approach using EB103 and Imugene's oncolytic virus CF33-CD19t. Recent major changes include the completion of the business combination in September 2023, closing of Series A preferred stock financing and private placement raising approximately $23.11 million in cash to advance clinical programs. The company operates primarily in the biopharmaceutical industry in the US and Canada, with a focus on innovative cancer immunotherapies. This strategic shift from a SPAC to an operating biopharma company marks its latest and most significant transformation. TradeUP Acquisition Corp. was founded in 2021 and is headquartered in New York, NY.